For example, the expression of glycyl-tRNA synthetase (GRS) was found to be an indicator of unfavorable outcomes in renal, urothelial, liver, breast and endometrial cancers (Thul and Lindskog, 2018). This evidence concerns the gene BCL2A1 and endometrial cancer.